<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01837901</url>
  </required_header>
  <id_info>
    <org_study_id>EST2</org_study_id>
    <nct_id>NCT01837901</nct_id>
  </id_info>
  <brief_title>Transcorneal Electrostimulation for Therapy of Retinitis Pigmentosa</brief_title>
  <official_title>Transkorneale Elektrostimulation Zur Therapie Bei Retinitis Pigmentosa - Eine Prospektive, Randomisierte, Einfach Blinde Folgestudie</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Okuvision GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Okuvision GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the long-term effects of transcorneal&#xD;
      electrostimulation (TcES) in patients with retinitis pigmentosa (RP). In a prior study&#xD;
      (NCT00804102) the results of short-term stimulation showed a positive effect on the visual&#xD;
      field and other parameters. In this study, the patients will be stimulated with either 0%,&#xD;
      150% or 200% of the individually determined phosphene threshold.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study was performed at the Centre for Ophthalmology, University of Tübingen, Germany. The&#xD;
      protocol was approved by the local ethics committee. All procedures followed were in&#xD;
      accordance with the ethical standards of the responsible committee on human experimentation&#xD;
      (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008.&#xD;
      Informed consent was obtained from all patients for being included in the study. The study&#xD;
      was conducted according to the standards of GCP, the European Union Directive for Medical&#xD;
      Devices, and the German Medical Product Law.&#xD;
&#xD;
      Patients were seen at 14 visits over a period of 78 weeks: one baseline visit (screening),&#xD;
      followed by 12 visits (in week 1-4 weekly, then in weeks 10, 16, 22, 28, 34, 40, 46 and 52;&#xD;
      dates varied a maximum of ± 1 week) including application of TcES for 52 weeks and one&#xD;
      follow-up visit (in week 78, dates varied a maximum of ± 1 week).&#xD;
&#xD;
      After inclusion patients were randomly assigned to TcES with 0 mA (sham), 150% or 200% of&#xD;
      their individual electrical phosphene threshold (EPT) current at 20 Hz.&#xD;
&#xD;
      Patients and technicians who performed kinetic perimetry, as well as full-field&#xD;
      electrophysiology (ERG), multifocal ERG (mfERG) and dark adaptation, were blinded to the&#xD;
      treatment group for the entire study period. The physicians who performed all other&#xD;
      examinations and TcES were not blinded to study treatment because they were responsible for&#xD;
      setting the stimulation parameters.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Field, III4e</measure>
    <time_frame>one year</time_frame>
    <description>Change in the area measured by kinetic visual field measurement</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Field, V4e</measure>
    <time_frame>one year</time_frame>
    <description>Change in the area measured by kinetic visual field measurement</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ERG B-wave</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ERG A-wave</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BCVA</measure>
    <time_frame>one year</time_frame>
    <description>Best corrected visual acuity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VFQ-25</measure>
    <time_frame>one year</time_frame>
    <description>Visual Function Questionnaire (VFQ-25)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dark Adaptation</measure>
    <time_frame>one year</time_frame>
    <description>Adaptation time, changes in pupil diameter, threshold to fullfield blue and red light is measured with a fullfield stimulus threshold test (FST) on the ESPION ERG machine (Diagnosys).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Retinitis Pigmentosa</condition>
  <arm_group>
    <arm_group_label>Sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>OkuStim is used to determine the phosphene threshold, device is turned on but no stimulation is performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>150%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OkuStim is used to determine the phosphene threshold, and then to administer transcorneal electrostimulation with a stimulation strength corresponding to 150% of the patient's phosphene threshold.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>200%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OkuStim is used to determine the phosphene threshold, and then to administer transcorneal electrostimulation with a stimulation strength corresponding to 200% of the patient's phosphene threshold.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcorneal electrostimulation</intervention_name>
    <arm_group_label>150%</arm_group_label>
    <arm_group_label>200%</arm_group_label>
    <arm_group_label>Sham</arm_group_label>
    <other_name>OkuStim</other_name>
    <other_name>TES</other_name>
    <other_name>TcES</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult subject with RP (rod-cone dystrophy)&#xD;
&#xD;
          -  BCVA 0.02 to 0.9&#xD;
&#xD;
          -  Reliable visual field measurements&#xD;
&#xD;
          -  Reliable ERG measurements&#xD;
&#xD;
          -  Skillful enough to use the device at home&#xD;
&#xD;
          -  Able to give consent and take part during the whole study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diabetic retinopathy&#xD;
&#xD;
          -  Neovascularisation of any origin&#xD;
&#xD;
          -  After arterial or venous occlusion&#xD;
&#xD;
          -  After retinal detachment&#xD;
&#xD;
          -  Silicone oil tamponade&#xD;
&#xD;
          -  Dry or exudative age-related macular degeneration&#xD;
&#xD;
          -  Macular edema&#xD;
&#xD;
          -  All forms of glaucoma&#xD;
&#xD;
          -  Any form of corneal degeneration that reduces visual acuity&#xD;
&#xD;
          -  Systemic diseases that are difficult to control or manage, that could endanger the&#xD;
             normal study schedule&#xD;
&#xD;
          -  Patients in a permanently poor general condition, which could hinder the regular&#xD;
             attendance at control examinations in the clinic&#xD;
&#xD;
          -  Forms of mental illness related to the bipolar affective and schizoid-affective&#xD;
             disorders, and all forms of dementia&#xD;
&#xD;
          -  Simultaneous participation in another interventional study or history of interventions&#xD;
             whose effect may still persist&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Florian Gekeler, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eberhard-Karls-Universität Tübingen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department für Augenheilkunde, Eberhard-Karls-Universität</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Naycheva L, Schatz A, Röck T, Willmann G, Messias A, Bartz-Schmidt KU, Zrenner E, Gekeler F. Phosphene thresholds elicited by transcorneal electrical stimulation in healthy subjects and patients with retinal diseases. Invest Ophthalmol Vis Sci. 2012 Nov 1;53(12):7440-8. doi: 10.1167/iovs.12-9612.</citation>
    <PMID>23049087</PMID>
  </reference>
  <reference>
    <citation>Gekeler F; Arbeitsgruppe Elektrostimulation des Department für Augenheilkunde am Universitäts-Klinikum Tübingen. [Transcorneal electrostimulation]. Ophthalmologe. 2012 Feb;109(2):129-35. doi: 10.1007/s00347-011-2450-6. German.</citation>
    <PMID>22350549</PMID>
  </reference>
  <reference>
    <citation>Schatz A, Röck T, Naycheva L, Willmann G, Wilhelm B, Peters T, Bartz-Schmidt KU, Zrenner E, Messias A, Gekeler F. Transcorneal electrical stimulation for patients with retinitis pigmentosa: a prospective, randomized, sham-controlled exploratory study. Invest Ophthalmol Vis Sci. 2011 Jun 23;52(7):4485-96. doi: 10.1167/iovs.10-6932.</citation>
    <PMID>21467183</PMID>
  </reference>
  <reference>
    <citation>Schatz A, Arango-Gonzalez B, Fischer D, Enderle H, Bolz S, Röck T, Naycheva L, Grimm C, Messias A, Zrenner E, Bartz-Schmidt KU, Willmann G, Gekeler F. Transcorneal electrical stimulation shows neuroprotective effects in retinas of light-exposed rats. Invest Ophthalmol Vis Sci. 2012 Aug 15;53(9):5552-61. doi: 10.1167/iovs.12-10037.</citation>
    <PMID>22807300</PMID>
  </reference>
  <reference>
    <citation>Röck T, Schatz A, Naycheva L, Gosheva M, Pach J, Wilhelm B, Peters T, Bartz-Schmidt KU, Zrenner E, Willmann G, Gekeler F. [Effects of transcorneal electrical stimulation in patients with Stargardt's disease]. Ophthalmologe. 2013 Jan;110(1):68-73. doi: 10.1007/s00347-012-2749-y. German.</citation>
    <PMID>23329121</PMID>
  </reference>
  <results_reference>
    <citation>Schatz A, Pach J, Gosheva M, Naycheva L, Willmann G, Wilhelm B, Peters T, Bartz-Schmidt KU, Zrenner E, Messias A, Gekeler F. Transcorneal Electrical Stimulation for Patients With Retinitis Pigmentosa: A Prospective, Randomized, Sham-Controlled Follow-up Study Over 1 Year. Invest Ophthalmol Vis Sci. 2017 Jan 1;58(1):257-269. doi: 10.1167/iovs.16-19906.</citation>
    <PMID>28114587</PMID>
  </results_reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>April 9, 2013</study_first_submitted>
  <study_first_submitted_qc>April 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2013</study_first_posted>
  <results_first_submitted>February 23, 2021</results_first_submitted>
  <results_first_submitted_qc>February 23, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 18, 2021</results_first_posted>
  <last_update_submitted>February 23, 2021</last_update_submitted>
  <last_update_submitted_qc>February 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Transcorneal electrostimulation</keyword>
  <keyword>TcES</keyword>
  <keyword>TES</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinitis</mesh_term>
    <mesh_term>Retinitis Pigmentosa</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited from the hospital's hereditary retinal degeneration clinic (Centre for Ophthalmology, University of Tuebingen, Tuebingen, Germany).&#xD;
Of 88 enrolled participants, 63 met the inclusion criteria and were randomized to treatment.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Sham</title>
          <description>OkuStim was used to determine the phosphene threshold, device was turned on but no stimulation was performed.</description>
        </group>
        <group group_id="P2">
          <title>150%</title>
          <description>OkuStim was used to determine the phosphene threshold, and then to administer transcorneal electrostimulation with a stimulation strength corresponding to 150% of the patient's phosphene threshold.</description>
        </group>
        <group group_id="P3">
          <title>200%</title>
          <description>OkuStim was used to determine the phosphene threshold, and then to administer transcorneal electrostimulation with a stimulation strength corresponding to 200% of the patient's phosphene threshold.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sham</title>
          <description>Device was turned on but no stimulation was performed.</description>
        </group>
        <group group_id="B2">
          <title>150%</title>
          <description>Transcorneal electrostimulation with 150% of phosphene threshold.</description>
        </group>
        <group group_id="B3">
          <title>200%</title>
          <description>Transcorneal electrostimulation with 200% of phosphene threshold.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="17"/>
            <count group_id="B4" value="52"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48" spread="15"/>
                    <measurement group_id="B2" value="42" spread="13"/>
                    <measurement group_id="B3" value="49" spread="16"/>
                    <measurement group_id="B4" value="46" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Visual Field, III4e</title>
        <description>Change in the area measured by kinetic visual field measurement</description>
        <time_frame>one year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sham</title>
            <description>Device was turned on but no stimulation was performed.</description>
          </group>
          <group group_id="O2">
            <title>150%</title>
            <description>Transcorneal electrostimulation with 150% of phosphene threshold.</description>
          </group>
          <group group_id="O3">
            <title>200%</title>
            <description>Transcorneal electrostimulation with 200% of phosphene threshold.</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Field, III4e</title>
          <description>Change in the area measured by kinetic visual field measurement</description>
          <units>deg2</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4835.29" lower_limit="2723.26" upper_limit="6947.32"/>
                    <measurement group_id="O2" value="4988.43" lower_limit="2799.14" upper_limit="7177.73"/>
                    <measurement group_id="O3" value="6234.59" lower_limit="4226.84" upper_limit="8242.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4488.39" lower_limit="2473.83" upper_limit="6502.95"/>
                    <measurement group_id="O2" value="4962.76" lower_limit="2765.44" upper_limit="7160.08"/>
                    <measurement group_id="O3" value="5878.75" lower_limit="3926.21" upper_limit="7831.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Visual Field, V4e</title>
        <description>Change in the area measured by kinetic visual field measurement</description>
        <time_frame>one year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sham</title>
            <description>Device was turned on but no stimulation was performed.</description>
          </group>
          <group group_id="O2">
            <title>150%</title>
            <description>Transcorneal electrostimulation with 150% of phosphene threshold.</description>
          </group>
          <group group_id="O3">
            <title>200%</title>
            <description>Transcorneal electrostimulation with 200% of phosphene threshold.</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Field, V4e</title>
          <description>Change in the area measured by kinetic visual field measurement</description>
          <units>deg2</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7135.77" lower_limit="4771.87" upper_limit="9499.66"/>
                    <measurement group_id="O2" value="7599.65" lower_limit="5004.80" upper_limit="10194.50"/>
                    <measurement group_id="O3" value="8303.59" lower_limit="6217.92" upper_limit="10389.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6730.20" lower_limit="4459.71" upper_limit="9000.69"/>
                    <measurement group_id="O2" value="7641.55" lower_limit="4945.26" upper_limit="10337.84"/>
                    <measurement group_id="O3" value="8112.18" lower_limit="6028.01" upper_limit="10196.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ERG B-wave</title>
        <time_frame>one year</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ERG A-wave</title>
        <time_frame>one year</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>BCVA</title>
        <description>Best corrected visual acuity</description>
        <time_frame>one year</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>VFQ-25</title>
        <description>Visual Function Questionnaire (VFQ-25)</description>
        <time_frame>one year</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dark Adaptation</title>
        <description>Adaptation time, changes in pupil diameter, threshold to fullfield blue and red light is measured with a fullfield stimulus threshold test (FST) on the ESPION ERG machine (Diagnosys).</description>
        <time_frame>one year</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>52 weeks treatment, follow-up visit after 72 weeks. AEs were recorded until the follow-up visit at 72 weeks.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Sham</title>
          <description>Device was turned on but no stimulation was performed.</description>
        </group>
        <group group_id="E2">
          <title>150%</title>
          <description>Transcorneal electrostimulation with 150% of phosphene threshold.</description>
        </group>
        <group group_id="E3">
          <title>200%</title>
          <description>Transcorneal electrostimulation with 200% of phosphene threshold.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Macular edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dry Eye Symptom</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="24" subjects_affected="14" subjects_at_risk="21"/>
                <counts group_id="E3" events="22" subjects_affected="14" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Ocular discomfort</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E3" events="4" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Ocular pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Subjective visual decrease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Skin irritation due to electrode</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Ocular infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Corneal erosion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>General and ocular infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-Ocular Adverse Events Total</sub_title>
                <description>All AEs that were non-ocular</description>
                <counts group_id="E1" events="16" subjects_affected="10" subjects_at_risk="22"/>
                <counts group_id="E2" events="20" subjects_affected="11" subjects_at_risk="21"/>
                <counts group_id="E3" events="17" subjects_affected="11" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. R. Schippert</name_or_title>
      <organization>Okuvision GmbH</organization>
      <phone>+49 7121 15935 ext 50</phone>
      <email>ruth.schippert@okuvision.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

